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Abstract
Background: Pelvic inflammatory disease (PID) is characterized by infection and inflammation of the upper genital
tract in women and is associated with health sequelae. We used a nationwide population-based retrospective
cohort study to explore the relationship between PID and the subsequent development of gynecological cancers
including ovarian, breast or uterine cancer.
Methods: We identified subjects diagnosed with PID between January 1st, 2000 and December 31st, 2002 in the
Taiwan National Health Insurance Research Database. A comparison cohort constructed for patients without PID
were matched according to age and sex. All PID patients and control groups were observed until diagnosed with
ovarian, breast or uterine cancer, or until death, withdrawal from the NHI system, or until December 31st, 2009.
Results: The PID cohort consisted of 32,268 patients, and an equal number of matched controls without PID. The
adjusted hazard ratio (HR) of ovarian, breast or uterine cancer in subjects with PID were: HR 1.326 (95 % confidence
interval: 0.775–2.269), HR: 1.039 (95 % confidence interval: 0.862–1.252), and HR: 1.439 (95 % confidence interval: 0.
853–2.426) respectively in comparison with controls during follow-up.
Conclusions: This large nationwide population-based cohort study suggests that there is no increased risk for
ovarian, breast or uterine cancer among women who have PID compared to a matching population.
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Background
Pelvic inflammatory disease (PID) is a polymicrobial in-
fection and inflammatory disorder of the upper female
genital tract, including the uterus, fallopian tubes, and
adjacent pelvic structures in women [1, 2]. It primarily
affects young, sexually active women. Most women with
PID can be treated successfully as outpatients with a
course of antibiotics for at least two weeks [3].
Without adequate treatment, PID may lead to major
sequelae, including ectopic pregnancy, pelvic pain, ab-
scesses, and infertility. Since infertility and low parity are
common complications of PID and are risk factors for
ovarian cancer, a few studies have demonstrated that
PID may increase the risk of ovarian cancer. A case-
control study in Canada with 450 histologically verified
primary epithelial ovarian cancer cases and 564 ran-
domly selected population controls done by Risch and
Howe, first reported that PID increased the risk of epi-
thelial ovarian cancer [4]. This association has been
interpreted in terms of inflammatory changes of the
ovarian surface epithelium [4]. However, an Italian case–
control study found no increased risk of ovarian cancer
with a history of PID (OR 0.7, 95 % confidence interval,
0.4–1.3) [5]. Genetic differences between racial or ethnic
groups, culture, and climate may partly explain these
controversial results. Recently, Lin and colleagues used a
large, nationwide health insurance database in Taiwan,
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demonstrating that the adjusted hazard ratio (HR) for
ovarian cancer in patients with PID was 1.92 (95 % CI
1 · 27–2 · 92) during the 3-year follow-up period [6].
However, this study was limited by a short period be-
tween the PID and the diagnosis of ovarian cancer (1–3
years) [7]. Furthermore, patients with International Clas-
sification of Diseases, ninth revision, clinical modifica-
tion (ICD-9-CM) code 616 (inflammatory disease of
cervix, vagina, and vulva) could have been wrongly clas-
sified in PID cases in that study [8]. For these reasons,
the first aim of this study is to explore whether PID in-
creases the risk of developing ovarian cancer with the
same database (Longitudinal Health Insurance Database
2005, LHID2005), but with a longer follow-up period ex-
cluding ICD-9-CM code 616 in PID cases. The second
aim of this study to investigate whether women with
PID raise the risk of developing uterine or breast cancer.
Methods
Data source
Instituted in 1995, the National Health Insurance (NHI)
program is a mandatory health insurance program that
offers comprehensive medical care coverage, including
outpatient, inpatient, emergency, and traditional Chinese
medicine, to all residents of Taiwan, with a coverage rate
of up to 98 % [9]. The NHI research database (NHIRD)
contains comprehensive information regarding clinical
visits, prescription details and diagnostic codes based on
ICD-9-CM. NHIRD is managed by the National Health
Research Institutes, and confidentiality is maintained ac-
cording to the directives of the Bureau of NHI. We used
LHID2005 as our study data source. LHID2005 contains
all the original claim data of 1,000,000 beneficiaries, ran-
domly sampled from the year 2005 Registry for Benefi-
ciaries (ID) of the NHIRD; everyone who was a
beneficiary of the National Health Insurance Program
within 2005 is in the population for random sampling.
There are approximately 25.68 million individuals in this
registry. All registration and claim data of the 1,000,000
individuals collected by the National Health Insurance
Program constitute the LHID2005. There were no
significant differences in gender distribution, age distri-
bution, or average insured payroll-related amount be-
tween the patients in the LHID2005 and those in the
original NHIRD (http://nhird.nhri.org.tw/en/index.htm).
Recently, using LHID2005, we have demonstrated an in-
creased risk of uterine but not ovarian and breast cancer
in women with polycystic ovary syndrome [10].
Study population
Using data extracted from the LHID2005, we conducted
a retrospective cohort study of patients who were newly
diagnosed with PID by an obstetrician-gynecologist be-
tween January 1st, 2000 and December 31st, 2002. To
ensure diagnostic validity and patient homogeneity, we
selected only patients who had at least two consensus
PID diagnoses for the study group. We excluded patients
who were diagnosed with PID between January 1st, 1996,
and December 31st, 1999. We also excluded patients
who were diagnosed with malignancies (ICD-9-CM
codes: 140-208) before they were diagnosed with PID.
For every PID patient included in the final cohort, one
age- and sex-matched control without PID, and any ma-
lignancy was randomly selected from LHID 2005 in the
same time period as PID patient. Random assignment
procedures were performed by SAS statistical software
and were based on random numbers generated from the
uniform distribution. All PID patients and controls were
observed until diagnosed with breast cancer (ICD-9-CM
code: 174-175), ovarian cancer (ICD-9-CM codes: 183),
uterine cancer (ICD-9-CM codes: 179, 181 and 182), or
until death, withdrawal from the NHI system, or until
December 31st, 2009. Our main dependent variable was
the occurrence of breast cancer, ovarian cancer, or uter-
ine cancer, as reported in the Registry for Catastrophic
Illness. For a diagnosis of cancer to be reported in the
Registry, histological confirmation is required. Common
co-morbidities including hypertension, diabetes mellitus,
dyslipidemia, congestive heart failure, chronic pulmon-
ary diseases, coronary artery diseases, and cerebrovascu-
lar diseases were also compared between PID and
controls. The study design and the criteria had been
used in similar studies [10–12].
Statistical analysis
The incidences of newly diagnosed breast cancer, ovarian
cancer, or uterine cancer in PID patients and controls
were calculated, and independent t tests and chi-squared
tests were used to examine differences in demographic
characteristics between the PID patients and controls. A
Cox proportional-hazards regression model was con-
structed to calculate the hazard ratio (HR) of breast can-
cer, ovarian cancer, or uterine cancer of the PID and
control cohorts, respectively. Control variables, such as
age, urbanization, monthly income, common co-
morbidities including hypertension, diabetes mellitus,
dyslipidemia, congestive heart failure, chronic pulmon-
ary diseases, coronary artery diseases, and cerebrovascu-
lar diseases were included as covariates in the
multivariate model to calculate adjusted HR. SAS statis-
tical software for Windows, version 9.3 (SAS Institute,
Cary, NC, USA), was used for data extraction, computa-
tion, data linkage, processing, and sampling. All other
statistical analyses were performed using SPSS statistical
software for Windows, version 20 (IBM, Armonk, NY,
USA). Results for comparisons with a P value of less
than .05 were considered as a statistically significant
relationship.
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Case control study design
For further confirmation of our study results, we also de-
signed a case control study. All subjects who were aged 20
and older and were newly diagnosed with uterine, ovarian
or breast cancer, respectively in 2009 were included as case
group. The controls were matched to cases by age, sex, and
index date with a ratio of 1:4. Diagnosis of PID before index
events was recorded during period of 2000-2009. The per-
centage of PID diagnosis in patients with uterine, ovarian,
breast cancer and three control cohorts were calculated re-
spectively. Odds ratios and 95 % confidence intervals were
also estimated by using multiple logistic regression.
Results
Our study included 32,268 PID patients and 32,268 con-
trols without PID. Comparisons of demographic and
clinical variables between PID patients and controls are
presented in Table 1. Median age at enrollment was
34.48 years (inter-quartile range [IQR], 27.46–
42.06 years), with a median follow-up period of 8.84 years
(IQR, 8.04–9.51 years) for both PID and controls. Co-
morbidities, including hypertension, diabetes mellitus,
dyslipidemia, congestive heart failure, cerebrovascular
disease and chronic pulmonary disease were more com-
mon in PID patients than controls. During this study
Table 1 Characteristics of patients with pelvic inflammatory disease and comparison subjects
PID (%) Control (%) P values
No. 32,268 32,268
Age (years) a 34.48 (27.46 – 42.06) 34.48 (27.47 – 42.06) 0.972
Distribution of age >0.999
20 – 39 22,221 (68.86) 22,221 (68.86)
40 – 59 9299 (28.82) 9299 (28.82)
> 60 748 (2.32) 748 (2.32)
Comorbidities
Hypertension 1985 (6.15) 1640 (5.08) <0.001b
Diabetes mellitus 1452 (4.50) 1106 (3.43) < 0.001b
Dyslipidemia 1816 (5.63) 1266 (3.92) < 0.001b
Coronary artery disease 51 (0.16) 37 (0.11) 0.137
Congestive heart failure 181 (0.56) 132 (0.41) 0.006b
Cerebrovascular disease 437 (1.35) 348 (1.08) 0.002b
Chronic pulmonary disease 1684 (5.22) 1230 (3.81) < 0.001b
Degree of urbanization < 0.001b
Urban 20,634 (63.95) 21,167 (65.60)
Suburban 8,998(27.89) 8,632 (26.75)
Rural 2,159 (6.69) 1,971 (6.11)
Income group < 0.001b
Low income 13,021 (40.35) 13,978 (43.32)
Median income 15,719 (48.71) 13,016 (40.34)
High income 3,528 (10.93) 5,274 (16.34)
Follow-up, years a 8.84 (8.04 – 9.51) 8.84 (8.04 – 9.51) >0.999
Newly diagnosed cancers, N (%)
Ovarian cancer 34 (0.11) 24 (0.07) 0.192
Breast cancer 228 (0.71) 222 (0.69) 0.777
Uterine cancer 35 (0.11) 27 (0.08) 0.313
Age of diagnosis of cancer (years) a
Ovarian cancer 45.50 (40.75 – 59.00) 46.50 (41.25 – 51.75) 0.183
Breast cancer 46.00 (40.00 – 52.00) 45.00 (41.00 – 50.00) 0.397
Uterine cancer 47.00 (40.00 – 56.00) 52.00 (45.00 – 55.00) 0.222
PID pelvic inflammatory disease
a Median (interquartile range)
bStatistical significance
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period, 34 ovarian cancers, 228 breast cancers, and 35
uterine cancers were observed in PID group and 24
ovarian cancers, 222 breast cancers, and 27 uterine can-
cers were observed in control group.
PID on risks of ovarian cancer, breast cancer, and uterine
cancer
After adjusting for age, co-morbidities, urbanization, and
monthly income, the adjusted HR of ovarian, breast and
uterine cancer in subjects with PID were 1.33 (95 % con-
fidence interval [CI] 0.78–2.27), 1.04 (95 % CI 0.86–
1.25), 1.44 (95 % CI 0.85–2.43) respectively in compari-
son with controls during follow-up (Table 2).
Results of case control study design
The percentage of PID history in patients with ovarian,
breast and uterine cancer, were 29.09 %, 19.38 %,
28.57 %, respectively (Tables 3, 4 and 5). The Odds ra-
tios of ovarian, breast and uterine cancer in subjects
with PID history at index date were 1.40 (95 % CI 0.72–
2.70), 1.12 (95 % CI 0.84–1.51), 1.64 (95 % CI 0.90–2.97)
respectively. The results are consistent with our cohort
study designs which showed that there is no increased
risk for ovarian, breast or uterine cancer among women
who have PID compared to a matching population.
Discussion
In a nationwide population-based study of ovarian can-
cer among PID patients in Taiwan, it was found that pa-
tients with PID had an increased risk of ovarian cancer
than patients without PID [6]. However, in our nation-
wide population-based study in Taiwan with the same
database, no significantly increased risk of subsequent
ovarian cancer was observed after a diagnosis of PID. The
discrepancy between such study and our study may have
come from differences in study periods (3 years versus
10 years), physician specialties for PID diagnosis (obstetri-
cian-gynecologist and other specialties versus obstetri-
cian–gynecologist), differences in diagnosis restrictions for
ovarian cancer (only patients with catastrophic illness cer-
tificate in our study) and PID ICD-9-CM coding (ICD-9-
CM codes 614-616 versus ICD-9-CM codes: 614-615). In
the cohort studied by Lin and colleagues, at least two
episodes of PID in relation to diagnosis of ovarian cancer
had to occur within 1–3 years [6]. In such a short period,
a causal relation between PID and ovarian cancer seems
less likely, and the inverse relationship between ovarian
cancer risk factor and PID cannot be excluded [7]. Fur-
thermore, both ICD-9-CM codes 614 and 615 refer to in-
flammatory disease of the ovary, fallopian tube, pelvic
cellular tissue, peritoneum, and uterus, except cervix, re-
spectively, which fit the diagnosis of PID. However, PID
cases in Lin and colleagues’ study also included ICD- 9-
CM code 616, which refers to the inflammatory disease of
cervix, vagina, and vulva. These infections affect only the
lower genital tract which is unrelated to or has not yet
progressed to PID. Thus, it would be inappropriate to in-
clude diseases pertinent to code 616 in this survey [8]. In
addition, our main dependent variables, the occurrence of
breast cancer, ovarian cancer, or uterine cancer, are col-
lected from the Registry for Catastrophic Illness and histo-
logical confirmation is required for a diagnosis of cancer
to be reported in the Registry, Therefore, the diagnosis of
cancer in our study is more precise.
Furthermore, our analysis showed that hypertension,
dyslipidemia and diabetes were more prevalent in
women with PID than in women without PID (Table 1).
Medical conditions associated with metabolic syndrome
such as hypertension, dyslipidemia and diabetes may
alter immune response and increase the risk of PID in
women [13, 14].
Ovarian, uterine and breast cancers are associated with
several risk factors, such as low parity and infertility
[15], which are common complications of PID [16, 17].
In addition, inflammatory response triggered by bacterial
or viral infection is a major factor for human carcino-
genesis [18, 19]. In addition of ovarian cancer, earlier re-
ports have suggested PID diagnosis is a risk factor for
cervical intra-epithelial neoplasia [20], cervical cancer
[21] and colorectal cancer [22]. In this study, we investi-
gated the hypothesis that PID may increase the risk of
uterine and breast cancers using a national health insur-
ance database. Our study suggests that there are no
Table 2 Hazard ratios of developing cancer between patients
with pelvic inflammatory disease and comparison subjects
Crude HR (95 % CI) Adjusted HR (95 % CI)a
Ovarian cancer 1.42 (0.84 – 2.39) 1.33 (0.78 – 2.27)
Breast cancer 1.03 (0.85 – 1.24) 1.04 (0.86 – 1.25)
Uterine cancer 1.35 (0.81 – 2.24) 1.44 (0.853 – 2.43)
HR hazard ratio, CI confidence interval
aAdjusted for age, hypertension, diabetes mellitus, dyslipidemia, coronary
artery disease, congestive heart failure, cerebrovascular disease, chronic
pulmonary disease, urbanization and income
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increased risks for both cancers among people who have
PID compared to a matching population.
Based on the relatively small number of patients diag-
nosed with cancer in our study, we collected annual num-
ber and incidence of ovarian, breast and uterine cancer of
Taiwan from Health Promotion Administration, Ministry
of Health and Welfare of Taiwan (https://cris.hpa.gov.tw/)
and compared above figures with our study. The results
showed that incidence rate of ovarian, breast or uterine
cancer was similar between general population of Taiwan
and subjects of our study (Additional file 1: Table S1).
Hence, we think the results of our study were representa-
tive and valid.
The strength of our study is the use of a population-
based data set with an enrollment of a large number of
subjects, enabling us to trace the subsequent risk of gyne-
cologic cancers in PID subjects and controls. Furthermore,
diagnosis of cancer in our study must be confirmed by
histological confirmation. In addition, our study design in-
cluded an unbiased participant selection process. Because
participation in NHI is mandatory and all residents of
Taiwan can access health care with low copayments, refer-
ral biases were low with high follow-up compliance.
Certain limitations to our findings should, however, be
considered: First, LHID2005 did not contain some im-
portant information regarding the studied subjects.
Some of the patient information which may influence
the risk of gynecologic cancers, such as smoking, alcohol
consumption, parity, infertility, age at menarche, and
family history of gynecologic cancers, were not available
for analysis [15]. Thus, we were unable to control these
potentially confounding factors. Second, diagnosis of
PID can only be confirmed with a positive bacterio-
logical test for lower genital tract infection such as chla-
mydia or gonorrhea [23]. PID diagnosis was entirely
determined using the ICD codes from the National
Health Insurance claim database, and there may be con-
cerns regarding the diagnostic accuracy of the database.
Third, the follow-up duration in this study (median
follow-up time 8.84 years) may have been insufficient for
detecting the carcinogenesis of certain types of cancer.
Most ovarian, uterine, and breast cancer occur after age
50 and the short follow-up time in this study may under-
estimate any possible association. Thus, future studies
with longer follow-up periods are required to determine
the long-term risk of cancer among PID patients. Forth,
our study is based on Taiwan National Health Insurance
research database and it’s difficult to apply the results of
our study to other regions with complete different popu-
lation composition, culture, or climate due to limited
geographical coverage. Finally, prevalence of PID diagno-
ses were identified using the ICD-9 codes from the data-
base may be underestimated as only subjects seeking
medical evaluation can be identified, leading to a likely
underestimation of the association between PID and gy-
necologic cancers.
Conclusions
In summary, our study did not support the idea that the
risk of ovarian cancer is higher in PID patients as shown
in an earlier report with same nationally representative
cohort database. We also demonstrated that PID diagno-
sis is not a risk factor for breast or uterine cancers.
Additional file
Additional file 1: Table S1. Number and incidence rate (IR, cancer
event per 100000 person years) of ovarian, breast or uterine cancer in
general population of Taiwan and PID subjects between 2000 and 2009.
(DOC 49 kb)
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